drugset
drugset / Trial / NCT05480501

Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia

NCT05480501 ↗

Phase 0 Unknown 9 enrolled Beijing Immunochina Medical Science & Technology Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a open-label to assess the efficacy and safety of IM19 CAR-T cells in R/R B-cell Acute Lymphoblastic Leukemia.

Timeline

Start
2022-07-11
Primary completion
2024-08-01
Completion
2024-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject IM19 CAR-T cells Cell therapy — —

Indications

leukemia